News
Only 26% of MM RCTs Report Racial Composition of Enrolled Patients
Despite improvement in overall survival for patients with multiple myeloma, racial minorities benefit less from these survival gains. Earlier research shows racial minorities are under-represented in multiple myeloma clinical trials, with scarce reporting of their...
Selected Journal Articles for the Week of January 18th
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice Background: We have performed a head to head comparison of all-oral triplet...
Delaying Daratumumab until Second Line in Transplant-ineligible Patients More Cost Effective
A study published in the Journal of Clinical Oncology suggests that using daratumumab in the first-line setting for transplant-ineligible patients may not be cost-effective under current pricing. the cost of daratumumab would need to be decreased by 67% for first-line...
Melflufen Plus Dexamethasone in RRMM Shows Durable Response
Updated survival data for the Phase II study O‐12‐M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy was published in the British Journal of Haematology. The...
Oncopeptides Enrolls 1st Patient in Phase 3 LIGHTHOUSE Study
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the first patient has been dosed in the phase 3 LIGHTHOUSE study, evaluating the efficacy and safety of a triple combination therapy with melflufen plus dexamethasone and subcutaneous daratumumab...
FDA Approval of Selinexor After At Least One Prior Therapy
The U.S. Food and Drug Administration (FDA) has approved XPOVIO® (selinexor) an oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at...
Featured Content
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
Join Our Community
By joining the MYELOMA360 community, you will receive regular updates with news, information, insights and expert opinions.
Of course, you can opt out at any time.